A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Nelitolimod (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Dynavax Technologies
- 20 Aug 2020 Status changed from completed to discontinued.
- 28 Aug 2018 According to a Dynavax Technologies media release, results (n=29) from this study published as a peer-reviewed paper in Cancer Discovery Journal.
- 29 Aug 2017 Status changed from active, no longer recruiting to completed.